Clinical Trial

Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia

Name: Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia — clinical trial record (NCT07010237)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a prospetive,Single-Center, Single-Arm, Phase IIB Clinical Study.This study aims to evaluate the efficacy and safety of dose-attenuated IST combined with Hetrombopag in elderly patients (≥65 years) with VSAA/SAA.

Trial Details

NCT Number	NCT07010237
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Sever Aplastic Anaemia, Elderly (People Aged 65 or More), Immunosuppressive Treatment
Enrollment	65 participants
Start Date	2025-02-01
Primary Completion	2028-12-31 (estimated)
Study Completion	2029-07-01 (estimated)
Updated on ClinicalTrials.gov	2025-06-08